|

Remibrutinib (Open Label) Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: LOU064

Pipeline

Phase 3: 2

Top Sponsors

  • Novartis Pharmaceuticals2

Indications

  • Secondary Progressive Multiple Sclerosis (SPMS)1
  • Multiple Sclerosis1
  • Generalized Myasthenia Gravis1
  • Cancer1

Birmingham, Alabama1 trial

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Alabama Neurology Associates PC

Phase 3

Phoenix, Arizona1 trial

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Neuromuscular Research Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.